Impact of Inflammatory Factors on Non-Lactating Mastitis and Glycemic Abnormalities

Significance of Non-Lactating Mastitis in Women’s Health

Non-lactating mastitis (NLM) is a prevalent and often under-discussed condition affecting women, particularly those aged between 20 and 40 years. This benign inflammation of breast tissue can manifest with various clinical symptoms, including localized swelling, pain, and in severe cases, the formation of abscesses (Qian et al., 2025). The psychological and physical toll of NLM can be significant, as many women experience anxiety, reduced quality of life, and challenges in personal relationships due to the condition (Qian et al., 2025). Understanding the impact of NLM and its correlation with glycemic abnormalities is crucial for improving women’s health outcomes, enhancing diagnostic accuracy, and guiding treatment strategies.

Inflammatory Factors Linked to Non-Lactating Mastitis Severity

Recent studies have identified several inflammatory markers that correlate with the severity of NLM, including interleukin-6 (IL-6), white blood cell (WBC) count, and high-sensitivity C-reactive protein (hs-CRP) (Qi et al., 2025). These inflammatory factors play a significant role in the body’s immune response and can exacerbate the condition. Elevated levels of IL-6 have been associated with increased breast tissue inflammation and can serve as a biomarker for the severity of NLM (Qi et al., 2025). Similarly, higher WBC counts indicate a heightened inflammatory response, reflecting the underlying pathophysiological processes at play.

These findings underscore the need for clinicians to consider inflammatory markers when assessing women with NLM, as they may not only reflect disease severity but also influence treatment decisions.

Relationship Between Glycemic Abnormalities and Mastitis

The interplay between glycemic control and inflammatory conditions such as NLM has garnered attention in recent research. Elevated blood glucose levels and insulin resistance are commonly linked with systemic inflammation, which can exacerbate the inflammatory response in mastitis (Qi et al., 2025). Dysglycemia has been shown to correlate with worse outcomes in various inflammatory diseases, and understanding this relationship in the context of NLM could lead to improved management strategies.

A multifactorial logistic regression analysis conducted in a recent study revealed a significant positive correlation between glycemic abnormalities and NLM severity, suggesting that individuals with poor glycemic control may experience more severe forms of mastitis (Qi et al., 2025). This association highlights the importance of monitoring and managing blood glucose levels in women presenting with NLM.

Role of IL-6, WBC, and hs-CRP in Mediating Disease Severity

The inflammatory markers IL-6, WBC count, and hs-CRP not only indicate the presence of inflammation but also play a mediating role in the relationship between glycemic abnormalities and the severity of NLM. Mediation analysis has shown that these factors partially mediate the effects of glycemic abnormalities on mastitis severity, with IL-6 exhibiting the most substantial mediating effect (Qi et al., 2025).

The findings suggest that addressing inflammation through targeted interventions may improve both glycemic control and the management of NLM, potentially leading to better health outcomes for affected women.

Implications for Treatment of Non-Lactating Mastitis and Metabolic Health

The interrelationship between inflammatory factors, glycemic control, and NLM severity presents a unique opportunity for healthcare providers to develop comprehensive treatment plans. Management strategies should focus not only on alleviating the symptoms of NLM but also on addressing underlying metabolic disorders. This holistic approach may include dietary interventions aimed at stabilizing blood glucose levels, physical activity to reduce inflammation, and pharmacological treatments targeting inflammatory pathways.

Furthermore, monitoring inflammatory markers such as IL-6, WBC count, and hs-CRP can aid in assessing treatment efficacy and guiding subsequent management decisions. This could lead to personalized care pathways that consider both the inflammatory and metabolic dimensions of NLM, ultimately improving the quality of life for women suffering from this condition.

FAQ

What is non-lactating mastitis?

Non-lactating mastitis is an inflammation of breast tissue that occurs in women who are not breastfeeding. It can present with symptoms such as breast pain, swelling, and redness.

How are inflammatory factors linked to non-lactating mastitis?

Inflammatory factors like IL-6, WBC count, and hs-CRP are associated with the severity of non-lactating mastitis, indicating the body’s inflammatory response to the condition.

What role do glycemic abnormalities play in non-lactating mastitis?

Glycemic abnormalities, such as elevated blood glucose levels, are positively correlated with the severity of non-lactating mastitis, suggesting that poor glycemic control may exacerbate the condition.

How can inflammatory markers be used in the management of non-lactating mastitis?

Monitoring inflammatory markers can help healthcare providers assess the severity of non-lactating mastitis and guide treatment decisions, potentially improving patient outcomes.

What are the best management strategies for non-lactating mastitis?

Effective management strategies may include dietary modifications, physical activity to reduce inflammation, pharmacological treatments targeting inflammation, and monitoring of glycemic levels.

References

1. Qi, D., Lin, Y., Zhang, J., & Wang, Y. (2025). Mediation effect of peripheral blood inflammatory factors in the association between severity of non-lactating mastitis and glycemic abnormalities. Journal of Medical Biochemistry. https://doi.org/10.5937/jomb0-52268
2. Al-kuraishy, H. M., & Al-Gareeb, A. I. (2023). The role of metabolic syndrome in the pathogenesis of Alzheimer’s disease: Cellular and subcellular alterations in underpinning a tale of two. Neuromolecular Medicine. https://doi.org/10.1007/s12017-025-08832-6
3. Batiha, G. E.-S., Al-kuraishy, H. M., & Al-Gareeb, A. I. (2023). SIRT1 pathway in Parkinson’s disease: A faraway snapshot but so close. Inflammopharmacology. https://doi.org/10.1007/s10787-022-01125-5
4. Breijyeh, Z., & Karaman, R. (2020). Comprehensive review on Alzheimer’s disease: Causes and treatment. Molecules. https://doi.org/10.3390/molecules25245789
5. Bosco, D. F., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011). Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis. Journal of Cellular and Molecular Medicine